Pyxis Oncology, Inc.
PYXS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $19 | $10 | $179 | $275 |
| Short-Term Investments | $107 | $110 | $0 | $0 |
| Receivables | $0 | $0 | $1 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $6 | $5 | $7 | $4 |
| Total Curr. Assets | $132 | $125 | $187 | $279 |
| Property Plant & Equip (Net) | $22 | $25 | $25 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $3 | $24 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $25 | $49 | $25 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $157 | $174 | $211 | $280 |
| Liabilities | – | – | – | – |
| Payables | $5 | $4 | $7 | $12 |
| Short-Term Debt | $1 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $8 | $0 | $0 |
| Other Curr. Liab. | $11 | $13 | $25 | $7 |
| Total Curr. Liab. | $18 | $26 | $32 | $19 |
| LT Debt | $19 | $20 | $19 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $2 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $19 | $22 | $19 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $20 | $21 | $19 | $0 |
| Total Liabilities | $36 | $48 | $51 | $19 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$364 | -$286 | -$212 | -$92 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $484 | $412 | $373 | $353 |
| Total Equity | $121 | $126 | $161 | $261 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $157 | $174 | $211 | $280 |
| Net Debt | $1 | $12 | -$160 | -$275 |